Background Neuraminidase inhibitors were widely used during the 2009–10 influenza A H1N1
pandemic, but evidence for their effectiveness in reducing mortality is uncertain. We did a …

The healthcare setting was important in the early spread of severe acute respiratory syndrome
(SARS) in both Toronto and Taiwan. Healthcare workers, patients, and visitors were at …

Establishing a clinical diagnosis of infection in residents of long-term–care facilities (LTCFs)
is difficult. As a result, deciding when to initiate antibiotics can be particularly challenging. …

Background The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
the cause of a rapidly spreading illness, Coronavirus Disease 2019 (COVID-19), affecting …

Background Severe acute respiratory syndrome (SARS) is a condition of unknown cause
that has recently been recognized in patients in Asia, North America, and Europe. This report …

Background In September 2012, the World Health Organization reported the first cases of
pneumonia caused by the novel Middle East respiratory syndrome coronavirus (MERS-CoV). …

While the antibody response to SARS-CoV-2 has been extensively studied in blood,
relatively little is known about the antibody response in saliva and its relationship to systemic …

The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear.
Although most randomized controlled trials have shown negative results, uncontrolled studies …

Background Acute myocardial infarction can be triggered by acute respiratory infections.
Previous studies have suggested an association between influenza and acute myocardial …

These clinical practice guidelines are an update of the guidelines published by the Infectious
Diseases Society of America (IDSA) in 2009, prior to the 2009 H1N1 influenza pandemic. …